Modality
Small Molecule
MOA
SHP2i
Target
GLP-1R
Pathway
Apoptosis
MCC
Development Pipeline
Preclinical
~Jun 2011
→ ~Sep 2012
Phase 1
~Dec 2012
→ ~Mar 2014
Phase 2
~Jun 2014
→ ~Sep 2015
Phase 3
~Dec 2015
→ ~Mar 2017
NDA/BLA
Jun 2017
→ Jul 2030
NDA/BLACurrent
NCT06111957
2,650 pts·MCC
2017-06→2030-07·Not yet recruiting
2,650 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-041mo awayNDA· MCC
2030-07-134.3y awayPh3 Readout· MCC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
NDA
2026-05-04 · 1mo away
MCC
Ph3 Readout
2030-07-13 · 4.3y away
MCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06111957 | NDA/BLA | MCC | Not yet recr... | 2650 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |